Edwards Lifesciences Co. (NYSE:EW) Holdings Raised by Tidal Investments LLC

Tidal Investments LLC raised its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 18.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,970 shares of the medical research company's stock after purchasing an additional 7,438 shares during the period. Tidal Investments LLC's holdings in Edwards Lifesciences were worth $3,477,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Prosperity Consulting Group LLC increased its position in Edwards Lifesciences by 3.6% during the fourth quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock valued at $289,000 after acquiring an additional 134 shares during the last quarter. Abacus Planning Group Inc. boosted its stake in shares of Edwards Lifesciences by 0.3% during the fourth quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company's stock valued at $2,977,000 after purchasing an additional 140 shares during the period. Moors & Cabot Inc. boosted its stake in shares of Edwards Lifesciences by 0.3% during the fourth quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company's stock valued at $4,041,000 after purchasing an additional 152 shares during the period. Quadrant Capital Group LLC boosted its stake in shares of Edwards Lifesciences by 3.1% during the fourth quarter. Quadrant Capital Group LLC now owns 5,180 shares of the medical research company's stock valued at $383,000 after purchasing an additional 156 shares during the period. Finally, Pegasus Asset Management Inc. boosted its stake in shares of Edwards Lifesciences by 0.4% during the fourth quarter. Pegasus Asset Management Inc. now owns 42,628 shares of the medical research company's stock valued at $3,156,000 after purchasing an additional 159 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on EW shares. Barclays boosted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Canaccord Genuity Group upped their price objective on shares of Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research note on Friday, April 25th. Wall Street Zen lowered shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Friday, May 16th. Robert W. Baird upped their price objective on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research note on Thursday, April 24th. Finally, Truist Financial lowered their price objective on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research note on Friday, April 11th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences has an average rating of "Hold" and a consensus target price of $80.20.

Edwards Lifesciences Trading Up 1.1%

Shares of Edwards Lifesciences stock traded up $0.83 during mid-day trading on Tuesday, hitting $75.82. 743,184 shares of the stock were exchanged, compared to its average volume of 4,643,344. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $95.25. The stock has a market capitalization of $44.48 billion, a price-to-earnings ratio of 10.88, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The company has a 50-day simple moving average of $72.86 and a 200 day simple moving average of $72.19. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. The company had revenue of $1.41 billion for the quarter, compared to analysts' expectations of $1.40 billion. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The firm's revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the company earned $0.66 EPS. Research analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other news, VP Daveen Chopra sold 1,500 shares of the firm's stock in a transaction that occurred on Thursday, May 22nd. The shares were sold at an average price of $75.08, for a total transaction of $112,620.00. Following the completion of the sale, the vice president now owns 33,496 shares of the company's stock, valued at approximately $2,514,879.68. This trade represents a 4.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the sale, the vice president now directly owns 46,936 shares of the company's stock, valued at $3,189,770.56. The trade was a 16.83% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 67,692 shares of company stock worth $4,822,074. Company insiders own 1.29% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.